Does Dr. TODD BELL have financial conflicts of interest?

Dr. TODD BELL (DPM) has received a total of $370 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $370 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Does Dr. TODD BELL receive research grants or speaking fees?

Dr. TODD BELL has received $370 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. TODD BELL

Q: Which pharmaceutical companies pay Dr. TODD BELL?

According to CMS Open Payments data, Dr. TODD BELL received funding from ORTHO DERMATOLOGICS, A DIVISION OF BAUSCH HEALTH US ($156), HIKMA PHARMACEUTICALS USA ($116), and HORIZON THERAPEUTICS PLC ($31).

DPMReal-Time Hydrated

Specialty: Podiatrist, Primary Podiatric Medicine

Practice Location: BLOOMFIELD, CT 06002

NPI Number: 1659320711

LIFETIME INDUSTRY VALUE

$370

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BELL is a verified Podiatrist, Primary Podiatric Medicine practitioner based in BLOOMFIELD, CT.

Between 2021 and 2025, Dr. BELL had an overall industry promotional and research financial footprint of $370 as recorded in the federal CMS Open Payments database.

$370 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BELL's primary funding source is ORTHO DERMATOLOGICS, A DIVISION OF BAUSCH HEALTH US, which accounts for $156 (representing 42.1% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ORTHO DERMATOLOGICS, A DIVISION OF BAUSCH HEALTH US

Rank 1

$156

42.1%

HIKMA PHARMACEUTICALS USA

Rank 2

$116

31.3%

HORIZON THERAPEUTICS PLC

Rank 3

$31

8.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.